PuSH - Publication Server of Helmholtz Zentrum München

Schlürmann, T.* ; Waschulzik, B.* ; Combs, S.E. ; Gempt, J.* ; Wiestler, B.* ; Weber, W.* ; Yakushev, I.*

Utility of amino acid PET in the differential diagnosis of recurrent brain metastases and treatment-related changes: A meta-analysis.

J. Nucl. Med. 64, 816-821 (2023)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
Amino acid PET is an established method to assist differential diagnosis of therapy-related changes versus recurrence in gliomas. However, its diagnostic value in brain metastases is yet to be determined. The goal of this study was to summarize evidence on the diagnostic utility of amino acid PET in recurrent brain metastases. Methods: The medical databases MEDLINE, EMBASE, and the Cochrane Library were screened for English-language studies with at least 10 patients who had undergone first-line treatment including radiotherapy and in whom a final diagnosis had been determined by histologic examination or imaging and clinical follow-up. Pooled estimates with 95% CIs were calculated. Heterogeneity was assessed using I2 statistics. Results: Following the above criteria, 12 studies with the tracers methyl-[11C]-methionine (n 5 6), O-(2-[18F]fluoroethyl)-L-tyrosine (n 5 3), methyl-[11C]-methionine and O-(2-[18F]fluoroethyl)-L-tyrosine (n 5 1), and 6-[18F]fluoro-L-dopa (n 5 2), with a total of 547 lesions in 397 patients, were included. Pooled sensitivity and specificity were 82% (95% CI, 76–86) and 84% (95% CI, 79–88), respectively. Pooled positive and negative predictive values were 84% (95% CI, 77–90) and 83% (95% CI, 77–88), respectively. Positive and negative likelihood ratios, and diagnostic odds ratio were 3.8 (95% CI 3.0–4.8), 0.3 (95% CI 0.2–0.3), and 16.7 (95% CI 10.8–25.9), respectively. Heterogeneity was overall low. Conclusion: The present meta-analysis indicates a good accuracy of amino acid PET in the differential diagnosis of recurrent brain metastases. In particular, specificity of 84% suggests that amino acid PET may reduce the number of invasive procedures and overtreatment in patients with treatment-related changes. This study provides class IIa evidence on the utility of amino acid PET in the differential diagnosis of recurrent brain metastases.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Cerebral Metastases ; Pet ; Pseudoprogression ; Radiation Necrosis ; Radiation Therapy; Positron-emission-tomography; Radiation Necrosis; F-18-fet Pet; O-(2-f-18-fluoroethyl)-l-tyrosine Pet; Stereotactic Radiosurgery; Fdg-pet; Tumors; Accuracy; Pseudoprogression; Radiotherapy
ISSN (print) / ISBN 0161-5505
e-ISSN 1535-5667
Journal Journal of Nuclear Medicine
Quellenangaben Volume: 64, Issue: 5, Pages: 816-821 Article Number: , Supplement: ,
Publisher Society of Nuclear Medicine and Molecular Imaging
Publishing Place 1850 Samuel Morse Dr, Reston, Va 20190-5316 Usa
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute of Radiation Medicine (IRM)